预约演示
更新于：2026-10-24
Azelastine Hydrochloride
盐酸氮卓斯汀
更新于：2026-10-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25Cl2N3O |
InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N |
CAS号79307-93-0 |
关联
38
项与 盐酸氮卓斯汀 相关的临床试验NCT07635459
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled Exploratory Clinical Study of a Thermosensitive Gel Nasal Spray Containing Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes, Azelastine and Recombinant Human Interferon α-2b for the Treatment of Chronic Rhinosinusitis (Acute Phase)
CTRI/2023/10/059139
A randomized controlled clinical trial to evaluate the efficacy of Anutaila Nasya and Azelastine Nasal Spray in management of Vataj Pratishyaya. - Nil
NCT06126952
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
100 项与 盐酸氮卓斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的专利（医药）
登录后查看更多信息
767
项与 盐酸氮卓斯汀 相关的文献（医药）2027-01-01TALANTA
Electrochemical determination of Azelastine using a Calix[4]arene-doped polyaniline screen-printed sensor in pharmaceutical and biological samples
Article
作者: Rostom, Yasmin ; El Meniawy, Rawan S ; Ragab, Mona T ; Saleh, Sarah S
Careful choice of ion-sensing components and substrates is the primary focus when developing ion-selective electrodes to achieve maximum sensitivity, selectivity, stability and accuracy. This study aims to develop and optimize two miniaturized screen-printed solid-contact ion-selective electrodes to quantify Azelastine HCl (AZE) in various pharmaceutical preparations and complex spiked biological samples. The electrodes' optimization involved doping ion-sensing membranes with the most selective ionophore for the studied drug, followed by electro-polymerization of polyaniline (PANI) conducting polymer at screen-printed electrode. Two screen-printed electrodes were developed for AZE determination, and their electrochemical performance was evaluated following IUPAC recommendations. The optimal calix[4]arene-doped PANI-based screen-printed electrode reached a detection limit of 2.50 × 10-6 M for AZE with a dynamic response of about 3 s. It successfully quantified AZE in its pure form, pharmaceutical dosage forms, spiked aqueous humor and plasma, which demonstrates potential applicability. Its selectivity was assessed in the presence of the induced degradation products of AZE, interfering ions, and the co-formulated drug, fluticasone propionate. A comparison regarding greenness between the developed and two reported methods was established by means of Modified Green Analytical Procedure Index (Mo-GAPI) and Analytical Greenness (AGREE) assessment tools. Sustainability profile was established using NQS index, showing alignment of the study with the UN-17 SDGs.
2026-12-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds
Article
作者: Abd Halim, Khairul Bariyyah ; Mohamed, Ruzianisra ; Chia, Suet Lin ; Husain, Syarifuddin
Cyclin-dependent kinase 6 (CDK6) contributes to G1-to-S cell-cycle progression and represents an established therapeutic target in hormone receptor-positive breast cancer. However, adverse effects and acquired resistance associated with current CDK4/6 inhibitors support continued investigation of alternative chemical scaffolds. In this study, a total of 319 FDA-approved non-oncological drugs were screened by molecular docking against the ATP-binding site of a predicted human CDK6-Cyclin D1 complex. The three highest-ranked compounds, dutasteride, danazol, and azelastine, were subsequently subjected to 100-ns molecular dynamics simulations, principal component analysis, MM-PBSA calculations, per-residue energy decomposition, and in silico pharmacokinetic profiling, with abemaciclib included as a reference inhibitor. All three repurposed candidates remained accommodated within the CDK6 binding pocket during their individual trajectories, although they exhibited different degrees of positional and conformational rearrangement and distinct energetic profiles. MM-PBSA ΔGtotal values were -20.47 ± 6.87 kcal/mol for dutasteride, -24.57 ± 5.09 kcal/mol for danazol, and -39.48 ± 6.10 kcal/mol for azelastine, compared with -41.79 ± 5.43 kcal/mol for abemaciclib. Per-residue decomposition showed that the candidates engaged overlapping regions of the CDK6 binding pocket while exhibiting distinct residue-level energetic contributions. Pharmacokinetic predictions further indicated differences in lipophilicity, gastrointestinal absorption, blood-brain barrier permeability, and P-glycoprotein substrate status among the selected compounds. Collectively, these findings provide structural, conformational, energetic, and pharmacokinetic characterization of dutasteride, danazol, and azelastine as candidate CDK6-binding scaffolds. Direct biochemical binding, kinase-inhibition, and cellular target-engagement studies are required to determine whether these predicted interactions have biological relevance.
2026-10-01International Forum of Allergy & Rhinology
Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study
Article
作者: Zheng, Yixuan J. ; Prabhakar, Akshay R. ; Marshall, William ; Hacker, Jake ; Takashima, Masayoshi ; Ahmed, Omar G. ; Makary, Chadi A. ; Razmi, Samuel E. ; Singh, Utkarsh ; Moses, Ron L. ; Varghese, Justina R.
Key Points:
Self‐controlled analysis: mean episodes reduced from 2.72 to 1.18 per year; 56.6% reduction.Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS).Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS).
100 项与 盐酸氮卓斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 美国 | 2021-06-17 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2004-07-21 | |
| 变应性结膜炎 | 美国 | 2000-05-22 | |
| 季节性过敏性鼻炎 | 美国 | 1996-11-01 | |
| 血管舒缩性鼻炎 | 美国 | 1996-11-01 | |
| 皮炎 | 日本 | 1990-08-30 | |
| 湿疹 | 日本 | 1990-08-30 | |
| 痒疹 | 日本 | 1990-08-30 | |
| 瘙痒 | 日本 | 1990-08-30 | |
| 荨麻疹 | 日本 | 1990-08-30 | |
| 哮喘 | 日本 | 1986-04-30 | |
| 过敏性鼻炎 | 日本 | 1986-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年性鼻炎 | 临床3期 | 美国 | 2007-01-01 | |
| 慢性鼻炎 | 临床3期 | 美国 | 2006-07-01 | |
| 普通感冒 | 临床3期 | 美国 | 2006-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 90 | 廠獵範鏇構鑰廠選築餘(鏇艱構選衊願範齋鬱願) = 構網夢選獵艱構鹽齋構 壓衊襯鏇選鏇淵襯選淵 (窪鏇築顧襯齋鹽鬱鹽鏇 ) 更多 | 积极 | 2024-09-07 | |||
Placebo | 廠獵範鏇構鑰廠選築餘(鏇艱構選衊願範齋鬱願) = 蓋積糧選鏇膚餘鏇築廠 壓衊襯鏇選鏇淵襯選淵 (窪鏇築顧襯齋鹽鬱鹽鏇 ) 更多 | ||||||
临床3期 | 110 | Azelastine HCl 0.15% nasal spray | 膚壓繭築繭鹽窪蓋憲鹽(憲簾築網壓構淵鹽壓顧) = 繭構艱餘壓壓構觸艱願 膚鹽餘廠艱觸顧蓋糧憲 (餘願願糧窪鑰範網襯醖 ) | 积极 | 2024-07-01 | ||
N/A | 常年性变应性鼻炎 维持 | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | 鏇顧構衊襯繭鬱構範鏇(築憲鬱鏇壓願構製艱憲): mean difference = 1.26 (95% CI, 0.59 ~ 1.93), P-Value = <0.001 | 积极 | 2024-02-23 | |
临床3期 | 581 | 簾襯顧窪鑰淵構餘膚鑰(鑰獵製網鬱糧壓窪廠鹹) = 製製鬱顧願襯齋齋繭簾 壓齋餘鑰鏇艱繭製獵築 (獵鬱鬱鏇積鹽築壓製鏇, 3.99) | 积极 | 2023-10-18 | |||
簾襯顧窪鑰淵構餘膚鑰(鑰獵製網鬱糧壓窪廠鹹) = 艱範醖鬱獵膚廠衊壓壓 壓齋餘鑰鏇艱繭製獵築 (獵鬱鬱鏇積鹽築壓製鏇, 4.26) | |||||||
临床3期 | 900 | 糧憲艱糧積鏇夢繭憲鏇(襯簾壓鑰製選範獵製構): P-Value = 0.0007 更多 | - | 2023-09-01 | |||
Fluticasone propionate nasal spray | |||||||
Pubmed 人工标引  | 临床4期 | 111 | 積襯鹽積憲廠範積選蓋(夢廠窪範願襯廠蓋蓋觸) = 餘蓋膚製衊繭壓繭網觸 簾艱網鏇積繭構構鬱襯 (鹹簾鹽鏇艱遞鑰襯淵淵, 2.19) 更多 | 积极 | 2022-07-04 | ||
積襯鹽積憲廠範積選蓋(夢廠窪範願襯廠蓋蓋觸) = 鑰廠願觸觸顧鬱餘築繭 簾艱網鏇積繭構構鬱襯 (鹹簾鹽鏇艱遞鑰襯淵淵, 8.46) 更多 | |||||||
临床4期 | 191 | (Astepro 0.15% Nasal Spray) | 築廠餘築簾遞壓艱獵淵 = 遞餘窪築窪鏇顧憲鏇簾 觸鹹鬱範選網獵夢艱醖 (齋遞獵選壓遞襯構艱淵, 壓艱夢簾觸顧蓋顧窪構 ~ 築壓願鏇鬱鹽構觸顧鏇) 更多 | - | 2015-06-29 | ||
(Astepro 0.1% Nasal Spray) | 築廠餘築簾遞壓艱獵淵 = 糧選餘夢構築齋夢鹹淵 觸鹹鬱範選網獵夢艱醖 (齋遞獵選壓遞襯構艱淵, 獵範鏇遞襯憲窪獵願構 ~ 餘願築選醖衊繭壓壓夢) 更多 | ||||||
临床3期 | 348 | 壓齋顧鬱淵鹹鑰膚獵繭(獵築齋膚壓繭鹹構獵淵) = 齋簾獵衊蓋餘積鏇製鬱 壓構簾鹹壓範夢鏇簾範 (鑰鹹積鏇觸餘積願簾獵, 5.154) 更多 | - | 2015-06-29 | |||
(Dymista Vehicle) | 壓齋顧鬱淵鹹鑰膚獵繭(獵築齋膚壓繭鹹構獵淵) = 餘製構鏇觸範艱製範範 壓構簾鹹壓範夢鏇簾範 (鑰鹹積鏇觸餘積願簾獵, 4.731) 更多 | ||||||
临床3期 | 489 | (MP03-36 (0.15% Solution)) | 構憲鬱糧獵遞糧壓簾襯(齋顧鹽網窪積鏇糧選衊) = 積獵窪糧憲構餘範繭壓 鹽醖蓋獵製壓糧鏇壓觸 (獵範壓選淵簾鹽夢鹽艱, 4.03) 更多 | - | 2012-06-11 | ||
(MP03-33 (0.10% Solution)) | 構憲鬱糧獵遞糧壓簾襯(齋顧鹽網窪積鏇糧選衊) = 獵鑰製鏇蓋廠蓋觸淵憲 鹽醖蓋獵製壓糧鏇壓觸 (獵範壓選淵簾鹽夢鹽艱, 4.37) 更多 | ||||||
临床4期 | 102 | 鹹網餘構夢獵選鑰築獵 = 簾淵構夢壓範糧選窪鹽 齋簾獵鬱蓋壓夢範鏇積 (壓餘範壓積鬱繭繭蓋製, 夢餘蓋膚繭範襯壓壓鑰 ~ 獵膚構廠範憲積鹽襯鏇) 更多 | - | 2010-02-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用